Literature DB >> 33271757

The Biotechnological Potential of Pediococcus spp. Isolated from Kombucha Microbial Consortium.

Camelia Filofteia Diguță1, George Daniel Nițoi1, Florentina Matei1, Gabriela Luță1, Călina Petruța Cornea1.   

Abstract

In the past decade, the probiotic market has grown rapidly, both for foods and supplements intended to enhance wellness in healthy individuals. Different lactic acid bacteria (LAB), especially Lactobacillus spp., of different origins have already been used to develop commercial probiotic products. Nowadays, LAB new alternative sources, such as non-dairy fermented food products, are being exploited. One such source is Kombucha, a fermented low-alcohol beverage made of tea leaves. In this regard, we tested seven Pediococcus spp. strains isolated from a local industrial Kombucha for their biotechnological potential. Two, out of the seven isolates, identified as Pediococcus pentosaceus (L3) and Pediococcus acidiliactici (L5), were selected as successful candidates for the food industry, due to their probiotic and technological properties. In regard to their resistance in the gastro-intestinal tract, both selected strains were tolerant to a pH of 3.5, presence of 0.3% pepsin, and 0.5% bile salt concentration. On the antagonistic side, the fresh suspension of selected isolates had high inhibitory activity against pathogenic bacteria, such as Salmonella enterica Typhimurium, Listeria monocytogenes, Listeria ivanovii, Bacillus cereus, Proteus hauseri, and methicillin resistant Staphylococcus aureus. In addition, moderate to high inhibitory activity was noticed against foodborne molds (e.g., Penicillium expansum and Penicillium digitatum). These safety issues were supported by their negative hemolytic activity and good antioxidant potential (56-58%). Selected isolates were sensitive to ampicillin, penicillin, erythromycin, and lincomycin, while a broad range of other antibiotics were not effective inhibitors. On the technological side, both strains tolerated 5% NaCl and, during the freeze-drying process, had a good survival rate (86-92%). The selected Pediococcus strains have proven properties to be used for further development of functional products.

Entities:  

Keywords:  Kombucha; Pediococcus spp.; antimicrobial; lactic acid bacteria (LAB); lyophilization; probiotic

Year:  2020        PMID: 33271757     DOI: 10.3390/foods9121780

Source DB:  PubMed          Journal:  Foods        ISSN: 2304-8158


  5 in total

Review 1.  Pediococcus pentosaceus: Screening and Application as Probiotics in Food Processing.

Authors:  Yining Qi; Le Huang; Yan Zeng; Wen Li; Diao Zhou; Jianhua Xie; Junyan Xie; Qiang Tu; Dun Deng; Jia Yin
Journal:  Front Microbiol       Date:  2021-12-16       Impact factor: 5.640

2.  Probiotic Properties of Bifidobacterium longum KABP042 and Pediococcus pentosaceus KABP041 Show Potential to Counteract Functional Gastrointestinal Disorders in an Observational Pilot Trial in Infants.

Authors:  Erola Astó; Pol Huedo; Tatiana Altadill; Meritxell Aguiló García; Maura Sticco; Marta Perez; Jordi Espadaler-Mazo
Journal:  Front Microbiol       Date:  2022-01-12       Impact factor: 5.640

3.  Microbial Diversity and Characteristics of Kombucha as Revealed by Metagenomic and Physicochemical Analysis.

Authors:  Mayank Kaashyap; Marc Cohen; Nitin Mantri
Journal:  Nutrients       Date:  2021-12-13       Impact factor: 5.717

Review 4.  Positive biofilms to guide surface microbial ecology in livestock buildings.

Authors:  Virgile Guéneau; Julia Plateau-Gonthier; Ludovic Arnaud; Jean-Christophe Piard; Mathieu Castex; Romain Briandet
Journal:  Biofilm       Date:  2022-04-19

5.  Preparation and Characterization of Calcium-Incorporated Rosa roxburghii Tratt and Its Efficacy on Bone Mineral Density in Rats.

Authors:  Yanfang Yan; Zhongsheng Luo; Leilei He; Fuxiao Wei; Ming Gao; Xiaofang Cui; Juan Yang; Yichun Sun; Lilang Li; Lishou Yang; Tingfei Deng; Xiong Pan; Mei Peng; Yunfei Tan; Zhengbin An; Liangqun Li; Xiaosheng Yang
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-20       Impact factor: 2.650

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.